These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 38567631)

  • 1. The potential of EZH2 expression to facilitate treatment choice in stage II colorectal adenocarcinoma.
    Zhu X; He L; Zheng Z; Wang Y; Yang J; Zhang B; Wang C; Li Z
    Histol Histopathol; 2024 Oct; 39(10):1371-1379. PubMed ID: 38567631
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Loss of enhancer of zeste homologue 2 (EZH2) at tumor invasion front is correlated with higher aggressiveness in colorectal cancer cells.
    Böhm J; Muenzner JK; Caliskan A; Ndreshkjana B; Erlenbach-Wünsch K; Merkel S; Croner R; Rau TT; Geppert CI; Hartmann A; Roehe AV; Schneider-Stock R
    J Cancer Res Clin Oncol; 2019 Sep; 145(9):2227-2240. PubMed ID: 31317325
    [TBL] [Abstract][Full Text] [Related]  

  • 3. EZH2 and STAT6 expression profiles are correlated with colorectal cancer stage and prognosis.
    Wang CG; Ye YJ; Yuan J; Liu FF; Zhang H; Wang S
    World J Gastroenterol; 2010 May; 16(19):2421-7. PubMed ID: 20480530
    [TBL] [Abstract][Full Text] [Related]  

  • 4. LGR5 and CD133 as prognostic and predictive markers for fluoropyrimidine-based adjuvant chemotherapy in colorectal cancer.
    Stanisavljević L; Myklebust MP; Leh S; Dahl O
    Acta Oncol; 2016 Dec; 55(12):1425-1433. PubMed ID: 27435662
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic value of histone marks H3K27me3 and H3K9me3 and modifying enzymes EZH2, SETDB1 and LSD-1 in colorectal cancer.
    Carvalho S; Freitas M; Antunes L; Monteiro-Reis S; Vieira-Coimbra M; Tavares A; Paulino S; Videira JF; Jerónimo C; Henrique R
    J Cancer Res Clin Oncol; 2018 Nov; 144(11):2127-2137. PubMed ID: 30105513
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunohistochemistry-Based Consensus Molecular Subtypes as a Prognostic and Predictive Biomarker for Adjuvant Chemotherapy in Patients with Stage II Colorectal Cancer.
    Li Y; Yao Q; Zhang L; Mo S; Cai S; Huang D; Peng J
    Oncologist; 2020 Dec; 25(12):e1968-e1979. PubMed ID: 32926498
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of EZH2 expression is associated with the proliferation, apoptosis, and migration of SW620 colorectal cancer cells in vitro.
    He SB; Zhou H; Zhou J; Zhou GQ; Han T; Wan DW; Gu W; Gao L; Zhang Y; Xue XF; Zhang LF; Fei M; Hu SQ; Yang XD; Zhu XG; Wang L; Li DC
    Exp Biol Med (Maywood); 2015 Apr; 240(4):458-66. PubMed ID: 25005166
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic Value of TWIST1 and EZH2 Expression in Colon Cancer.
    Abdel Raouf SM; Ibrahim TR; Abdelaziz LA; Farid MI; Mohamed SY
    J Gastrointest Cancer; 2021 Mar; 52(1):90-98. PubMed ID: 31823218
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The association and prognostic impact of enhancer of zeste homologue 2 expression and epithelial-mesenchymal transition in resected lung adenocarcinoma.
    Matsubara T; Toyokawa G; Takada K; Kinoshita F; Kozuma Y; Akamine T; Shimokawa M; Haro A; Osoegawa A; Tagawa T; Mori M
    PLoS One; 2019; 14(5):e0215103. PubMed ID: 31042721
    [TBL] [Abstract][Full Text] [Related]  

  • 10. O-GlcNAcylation promotes colorectal cancer metastasis via the miR-101-O-GlcNAc/EZH2 regulatory feedback circuit.
    Jiang M; Xu B; Li X; Shang Y; Chu Y; Wang W; Chen D; Wu N; Hu S; Zhang S; Li M; Wu K; Yang X; Liang J; Nie Y; Fan D
    Oncogene; 2019 Jan; 38(3):301-316. PubMed ID: 30093632
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mitochondrial DNA Copy Number as a Biomarker for Guiding Adjuvant Chemotherapy in Stages II and III Colorectal Cancer Patients with Mismatch Repair Deficiency: Seeking Benefits and Avoiding Harms.
    Chen M; Deng S; Cao Y; Wang J; Zou F; Gu J; Mao F; Xue Y; Jiang Z; Cheng D; Huang N; Huang L; Cai K
    Ann Surg Oncol; 2024 Sep; 31(9):6320-6330. PubMed ID: 38985229
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of the enhancer of zeste homolog 2 in biopsy specimen predicts chemoresistance and survival in advanced non-small cell lung cancer receiving first-line platinum-based chemotherapy.
    Xu C; Hao K; Hu H; Sheng Z; Yan J; Wang Q; Yu L
    Lung Cancer; 2014 Nov; 86(2):268-73. PubMed ID: 25262426
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The relationship between EZH2 expression and microRNA-31 in colorectal cancer and the role in evolution of the serrated pathway.
    Kurihara H; Maruyama R; Ishiguro K; Kanno S; Yamamoto I; Ishigami K; Mitsuhashi K; Igarashi H; Ito M; Tanuma T; Sukawa Y; Okita K; Hasegawa T; Imai K; Yamamoto H; Shinomura Y; Nosho K
    Oncotarget; 2016 Mar; 7(11):12704-17. PubMed ID: 26871294
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression and clinicopathological significance of EED, SUZ12 and EZH2 mRNA in colorectal cancer.
    Liu YL; Gao X; Jiang Y; Zhang G; Sun ZC; Cui BB; Yang YM
    J Cancer Res Clin Oncol; 2015 Apr; 141(4):661-9. PubMed ID: 25326896
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic significance of MUC2, CDX2 and SOX2 in stage II colorectal cancer patients.
    Ribeirinho-Soares S; Pádua D; Amaral AL; Valentini E; Azevedo D; Marques C; Barros R; Macedo F; Mesquita P; Almeida R
    BMC Cancer; 2021 Apr; 21(1):359. PubMed ID: 33823840
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of astrocyte-elevated gene-1 indicates prognostic value of fluoropyrimidine-based adjuvant chemotherapy in resectable stage III colorectal cancer.
    Lin LW; Lai PS; Chen YY; Chen CY
    Pathol Int; 2021 Nov; 71(11):752-764. PubMed ID: 34528330
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognosis of early-onset vs. late-onset stage II/III colorectal cancer patients with adjuvant chemotherapy: a multicenter propensity score matched study.
    Okamoto K; Ozawa T; Nozawa H; Sasaki K; Murono K; Emoto S; Yamauchi S; Sugihara K; Ishihara S
    Int J Clin Oncol; 2024 Nov; 29(11):1721-1729. PubMed ID: 39143428
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinicopathological predictors of benefit from adjuvant chemotherapy for stage C colorectal cancer: Microsatellite unstable cases benefit.
    Thomas ML; Hewett PJ; Ruszkiewicz AR; Moore JW
    Asia Pac J Clin Oncol; 2015 Dec; 11(4):343-51. PubMed ID: 26471980
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Overexpression of TP53 protein is associated with the lack of adjuvant chemotherapy benefit in patients with stage III colorectal cancer.
    Williams DS; Mouradov D; Browne C; Palmieri M; Elliott MJ; Nightingale R; Fang CG; Li R; Mariadason JM; Faragher I; Jones IT; Churilov L; Tebbutt NC; Gibbs P; Sieber OM
    Mod Pathol; 2020 Mar; 33(3):483-495. PubMed ID: 31471586
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A network-based predictive gene-expression signature for adjuvant chemotherapy benefit in stage II colorectal cancer.
    Cao B; Luo L; Feng L; Ma S; Chen T; Ren Y; Zha X; Cheng S; Zhang K; Chen C
    BMC Cancer; 2017 Dec; 17(1):844. PubMed ID: 29237416
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.